Edition:
United States

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

1.44USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,344
52-wk High
$6.43
52-wk Low
$1.37

Latest Key Developments (Source: Significant Developments)

Cesca Therapeutics Entered Amendment To Revolving Line Of Credit Facility
Wednesday, 18 Apr 2018 06:17am EDT 

April 18 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS SAYS ON APRIL 16, ENTERED AMENDMENT TO ITS REVOLVING LINE OF CREDIT FACILITY - SEC FILING.CESCA THERAPEUTICS - WITH AMENDED CREDIT AGREEMENT, ON APRIL 16, CO ENTERED INTO FIRST AMENDED AND RESTATED NOMINATION AND VOTING AGREEMENT.CESCA THERAPEUTICS - AMENDED NOMINATION AGREEMENT WILL TERMINATE ACCORDING TO ITS TERMS WHEN AND IF THE BOYALIFE OWNERSHIP PERCENTAGE FALLS BELOW 20%.  Full Article

Cesca Therapeutics Announces Release Of X-Mini Cell Selection Kit
Tuesday, 3 Apr 2018 08:30am EDT 

April 3 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC. ANNOUNCES RELEASE OF X-MINI CELL SELECTION KIT FOR THE CAR-T RESEARCH MARKET.  Full Article

Cesca Therapeutics Announces Pricing Of Public Offering
Wednesday, 29 Nov 2017 09:07am EST 

Nov 29 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 900,000 SHARES OF COMMON STOCK.CESCA THERAPEUTICS INC - PRICED REGISTERED PUBLIC OFFERING AT $3.00 PER SHARE​.  Full Article

Cesca Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 28 Nov 2017 05:20pm EST 

Nov 28 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Cesca Therapeutics reports quarterly loss per share $0.24
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - Cesca Therapeutics Inc ::Cesca Therapeutics announces financial results for the three months ended September 30, 2017 and provides corporate update.Quarterly loss per share $0.24.Quarterly revenue $3.1 million versus $3.8 million.  Full Article

Cesca Therapeutics ‍receives Notice of Allowance for U.S. patent application covering a novel method of cell separation​
Tuesday, 3 Oct 2017 07:00am EDT 

Oct 3 (Reuters) - Cesca Therapeutics Inc : :Cesca Therapeutics Inc - ‍receives Notice of Allowance for U.S. patent application covering a novel method of cell separation​.  Full Article

Cesca Therapeutics says co entered into Amendment No. 1 to Revolving Credit Agreement with Boyalife Investment Fund II​
Friday, 22 Sep 2017 06:52am EDT 

Sept 22 (Reuters) - Cesca Therapeutics Inc :Cesca Therapeutics - ‍on September 13, 2017, co entered into an Amendment No. 1 to Revolving Credit Agreement with Boyalife Investment Fund II, Inc​.Cesca Therapeutics - amendedment amends Revolving Credit Agreement entered on March 6, 2017, by increasing borrowing availability to $10.0 million​.Cesca Therapeutics - ‍in connection with amendment, co entered amended and restated convertible promissory note to reflect new amount of $10.0 million​.  Full Article

Cesca Therapeutics announces distribution agreement with Boyalife WSN
Thursday, 24 Aug 2017 11:09am EDT 

Aug 24 (Reuters) - Cesca Therapeutics Inc :Cesca Therapeutics announces international distribution agreement with Boyalife WSN Ltd..‍Agreement to market and distribute Cesca's biobanking and point-of-care solutions in China, India, Singapore and Philippines​.  Full Article

Cesca Therapeutics says acquires cell processing systems of SynGen
Monday, 10 Jul 2017 07:45am EDT 

July 10 (Reuters) - Cesca Therapeutics Inc :Cesca therapeutics acquires the cell processing systems of syngen under asset acquisition agreement.Cesca therapeutics inc - wholly-owned subsidiary, thermogenesis corp., has entered into an asset acquisition agreement with syngen inc.Cesca therapeutics inc- ‍wholly-owned subsidiary, thermogenesis corp., has entered into an asset acquisition agreement with syngen inc​.Cesca therapeutics inc- ‍representative of syngen's majority shareholder, bay city capital, has joined board of directors of themogenesis​.Cesca therapeutics - philip coelho, co-founder and cto of syngen, has joined thermogenesis in chief technology officer role, effective immediately.Cesca therapeutics inc- ‍in exchange for assets, thermogenesis granted syngen 20% of its common stock and paid a one-time cash payment of $1 million​.  Full Article

Cesca Therapeutics Q3 loss per share $0.21
Thursday, 11 May 2017 04:16pm EDT 

May 11 (Reuters) - Cesca Therapeutics Inc ::Cesca Therapeutics announces fiscal third quarter and nine month 2017 financial and operating results and provides corporate update.Q3 revenue $3.3 million versus $2.8 million.Q3 loss per share $0.21.  Full Article

BRIEF-Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES EVALUATION AGREEMENT WITH THE UNIVERSITY OF NORTH CAROLINA LINEBERGER ADVANCED CELLULAR THERAPEUTICS FACILITY FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING